Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups

Breast cancer is the fifth leading cause of cancer-related deaths worldwide. The randomized controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2)–positive advanced breast cancer (ABC) have provided an evidence base for regulatory and reimbursement agencies to appraise t...

Descripción completa

Detalles Bibliográficos
Autores principales: Umemneku-Chikere, Chinyereugo M., Ayodele, Olubukola, Soares, Marta, Khan, Sam, Abrams, Keith, Owen, Rhiannon, Bujkiewicz, Sylwia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433866/
https://www.ncbi.nlm.nih.gov/pubmed/36059633
http://dx.doi.org/10.3389/fonc.2022.943154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433866/
https://www.ncbi.nlm.nih.gov/pubmed/36059633
http://dx.doi.org/10.3389/fonc.2022.943154

Ejemplares similares